A critical security bug could lead to remote device control, altered lab results, and more, putting patients in danger, agency warns.
Healthcare providers and lab workers using Illumina genetic sequencing instruments are advised to immediately patch the device software against a new vulnerability that the Food and Drug Administration says could put patients in danger.
Affected devices include Illumina NextSeq 550Dx, MiSeqDx, NextSeq 500, NextSeq 550, MiSeq, iSeq, and MiniSeq next-generation sequencing instruments, the FDA said.
The medical devices are used to test for genetic conditions and genetic sequencing, and the FDA said the bug, first detected on May 3, could be exploited by threat actors to take over the Illumina instruments. That would allow them to alter the operating system, access a customer's network, tamper with test results, or even steal data. The flaw affects the Local Run Manager software, the FDA added.
So far, there are no reports of the bug being exploited, the FDA said in a cybersecurity alert to health care providers; however, the agency asks "users to report any adverse events or suspected adverse events experienced with Illumina’s next-generation sequencing instruments."
About the Author(s)
You May Also Like
The fuel in the new AI race: Data
April 23, 2024Securing Code in the Age of AI
April 24, 2024Beyond Spam Filters and Firewalls: Preventing Business Email Compromises in the Modern Enterprise
April 30, 2024Key Findings from the State of AppSec Report 2024
May 7, 2024Is AI Identifying Threats to Your Network?
May 14, 2024
Black Hat USA - August 3-8 - Learn More
August 3, 2024Cybersecurity's Hottest New Technologies: What You Need To Know
March 21, 2024